Gregory Piazza Presents HI-PRO Trial Results on VTE at ESC Congress
Gregory Piazza, Director of the Vascular Medicine Section at Brigham and Women’s Hospital, posted on LinkedIn:
‘‘Venous thromboembolism (VTE) has traditionally been categorized as unprovoked and treated with extended anticoagulation or provoked and prescribed time-limited anticoagulation for 3 months.
What do we do with patients who have provoked events but other persistent risk factors like obesity or heart disease?
We answered this question in the HI-PRO randomized controlled trial presented in Madrid at the European Society of Cardiology Congress and simultaneously published in the New England Journal of Medicine.
The culmination of 5 years of blood, sweat, and almost tears, it would not have been possible without an amazing team, my co-investigators and the Thrombosis Research Group team!”
Watch the full video here.
Read the full article in NEJM.
Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind Pandey, Darsiya Krishnathasan, Candrika Khairani, Antoine Bejjani, Ruth Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Goldhaber
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Mar 15, 2026, 15:55Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 2
-
Mar 15, 2026, 14:09Abdul Mannan: A Red Eye, a Blood Clot, and Ibrutinib – The Clinical Tightrope
-
Mar 15, 2026, 14:02Denise M: Precision Hemostasis in Patient Blood Management
-
Mar 15, 2026, 13:57Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies
-
Mar 15, 2026, 13:52Valentin Ortiz-Maldonado: High-Impact Innovation in CAR-T Therapy Can Emerge From Academic Programmes
-
Mar 15, 2026, 13:45Tareq Abadl: Has Anyone Here Ever Taken an ALP Test Before?
-
Mar 14, 2026, 21:30Ayman Elbadawi: Why Does Stent Thrombosis Still Occur? Insights from the NCDR Data
-
Mar 14, 2026, 20:03Edward Adomako: Recognizing Thrombotic Thrombocytopenic Purpura as A Life-Threatening Emergency
-
Mar 14, 2026, 19:28Vishnu Priya Pulipati: Statins Beyond Cholesterol for Plaque Biology and Cardiovascular Risk Reduction